Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study.

Horstmann M, Banek S, Gakis G, Todenhöfer T, Aufderklamm S, Hennenlotter J, Stenzl A, Schwentner C; UroScreen study group.

Springerplus. 2014 Jan 13;3:24. doi: 10.1186/2193-1801-3-24. eCollection 2014.

PMID:
24478941
2.

Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.

Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhäusser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A; UroScreen Study Group.

BJU Int. 2012 Sep;110(5):699-708. doi: 10.1111/j.1464-410X.2011.10883.x. Epub 2012 Feb 7.

PMID:
22313585
3.

Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.

Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, Wellhäusser H, Kluckert M, Leng G, Nasterlack M, Lotan Y, Stenzl A, Brüning T; UroScreen Study Group.

Int Arch Occup Environ Health. 2014;87(7):715-24. doi: 10.1007/s00420-013-0916-3. Epub 2013 Oct 16.

PMID:
24129706
4.

Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.

Banek S, Schwentner C, Täger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M, Gakis G, Todenhöfer T, Hennenlotter J, Brüning T, Stenzl A; UroScreen Study Group.

Urol Oncol. 2013 Nov;31(8):1656-62. doi: 10.1016/j.urolonc.2012.04.015. Epub 2012 May 22.

PMID:
22621963
5.

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.

Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L.

Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040. Review.

PMID:
20082749
6.

Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study.

Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B; UroScreen Study Group.

BJU Int. 2013 Aug;112(4):E372-82. doi: 10.1111/j.1464-410X.2012.11666.x. Epub 2013 Jan 25.

PMID:
23350736
7.

Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.

Ahmad S, Aboumarzouk O, Somani B, Nabi G, Kata SG.

BJU Int. 2012 Dec;110(11 Pt B):E596-600. doi: 10.1111/j.1464-410X.2012.11326.x. Epub 2012 Jul 3.

PMID:
22758907
8.

Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies.

Hermann GG, Mogensen K, Toft BG, Glenthøj A, Pedersen HM.

Scand J Urol Nephrol. 2012 Feb;46(1):31-6. doi: 10.3109/00365599.2011.637954. Epub 2011 Dec 12.

PMID:
22150596
9.

The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines.

Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhäusser H, Stenzl A, Brüning T; UroScreen Group.

BJU Int. 2011 Aug;108(4):546-52. doi: 10.1111/j.1464-410X.2010.09971.x. Epub 2011 Jan 11. Erratum in: BJU Int. 2011 Oct;108(7):1232.

PMID:
21223477
10.

Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.

Ray ER, Chatterton K, Khan MS, Thomas K, Chandra A, O'Brien TS.

BJU Int. 2009 May;103(10):1363-7. doi: 10.1111/j.1464-410X.2008.08238.x. Epub 2008 Dec 8.

PMID:
19076151
11.

Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder.

Colombo R, Naspro R, Bellinzoni P, Fabbri F, Guazzoni G, Scattoni V, Losa A, Rigatti P.

Ther Clin Risk Manag. 2007 Dec;3(6):1003-7.

PMID:
18516260
12.

Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.

Kumar A, Kumar R, Gupta NP.

Jpn J Clin Oncol. 2006 Mar;36(3):172-5. Epub 2006 Mar 6.

PMID:
16520358
13.

Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.

Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.

Cancer Detect Prev. 2000;24(4):364-8.

PMID:
11059567
14.

Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.

Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.

J Urol. 2002 Aug;168(2):465-9.

PMID:
12131289
15.

UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary study.

Dodurga Y, Avcı CB, Yılmaz S, Nazlı O, Coğulu O, Cankaya T, Gündüz C.

Contemp Oncol (Pozn). 2013;17(2):156-60. doi: 10.5114/wo.2013.34619. Epub 2013 Apr 29.

PMID:
23788983
16.

Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma?

Sim HG, Lau WK, Olivo M, Tan PH, Cheng CW.

BJU Int. 2005 Jun;95(9):1215-8.

PMID:
15892804
17.

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.

Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R.

J Urol. 2008 Jun;179(6):2164-9. doi: 10.1016/j.juro.2008.01.105. Epub 2008 Apr 18.

PMID:
18423745
18.

Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.

Kehinde EO, Al-Mulla F, Kapila K, Anim JT.

Scand J Urol Nephrol. 2011 Mar;45(2):113-21. doi: 10.3109/00365599.2010.533694. Epub 2010 Nov 22.

PMID:
21091091
19.
20.

Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.

Todenhöfer T, Hennenlotter J, Tews V, Gakis G, Aufderklamm S, Kuehs U, Stenzl A, Schwentner C.

Urol Oncol. 2013 Oct;31(7):1148-54. doi: 10.1016/j.urolonc.2011.10.011. Epub 2011 Nov 29.

PMID:
22130125

Supplemental Content

Support Center